美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

亞盛醫藥

40.40

-0.6400-1.56%

盤後：40.400.00000.00%16:10 EDT

成交量：3,944.00

成交額：16.02萬

市值：37.64億

市盈率：-54.92

高：40.98

開：40.98

低：40.34

收：41.04

52周最高：48.45

52周最低：16.50

股本：9,316.78萬

流通股本：7,158.28萬

量比：0.28

換手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-0.7356

每股收益(LYR):-0.7356

淨資產收益率：-159.65%

總資產收益率：-22.77%

市淨率：40.26

市盈率(LYR):-54.92

資料載入中...

總覽公司新聞公告

亞盛醫藥-B：受託人就2022年受限制股份單位計劃購買5萬股

亞盛醫藥-B(06855)：受託人就2022年受限制股份單位計劃購買5萬股

亞盛醫藥4月4日成交額為172.07萬美元

亞盛醫藥4月3日成交額為162.57萬美元

【券商聚焦】浦銀國際予亞盛醫藥(06855)“買入”評級耐立克獲納醫保有望在2025年迎來強勁收入增速

【晨觀方正】亞盛醫藥B公司點評報告新 / 中遠海控2024年報點評 20250403

方正证券研究

亞盛醫藥上漲2.1%，報23.524美元/股，總市值20.48億美元

亞盛醫藥：全球化戰略加速，雙引擎驅動商業化高速發展

21世纪经济报道

亞盛醫藥4月1日成交額為160.94萬美元

亞盛醫藥上漲4.53%，報22.945美元/股，總市值19.98億美元

異動解讀 | 亞盛醫藥盤中大漲5.56%，創新藥佈局和業績增長獲市場認可

異動解讀 | 亞盛醫藥盤中大漲5.56%，業績超預期及產品管線進展引關注

亞盛醫藥全速前進背後

亞盛醫藥-B(06855)：受託人就2022年受限制股份單位計劃購買5萬股

年入9.81億元，同比高增342%，亞盛醫藥的“雪球越滾越大”

異動解讀 | 亞盛醫藥財報亮眼，盤中大漲6.44%

異動解讀 | 亞盛醫藥盤中大漲6.44%，年度營收暴增342%引發投資者熱情

拳頭產品國內銷售大增52%，亞盛醫藥去年虧損收窄，欲挑戰艾伯維血液腫瘤明星藥

亞盛醫藥-B績後漲超8% 公司全年收入同比增長342%

港股異動 | 亞盛醫藥-B(06855)績後再漲9% 耐立克銷售額顯著增長公司全年收入增超3.4倍

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":40.4,"timestamp":1757448000000,"preClose":41.04,"halted":0,"volume":3944,"hourTrading":{"tag":"盘后","latestPrice":40.4,"preClose":40.4,"latestTime":"16:10 EDT","volume":34,"amount":1373.36,"timestamp":1757448603723},"delay":0,"floatShares":71582800,"shares":93167803,"eps":-0.735552,"marketStatus":"已收盤","change":-0.64,"latestTime":"09-09 16:00:00 EDT","open":40.98,"high":40.98,"low":40.3391,"amount":160198.261,"amplitude":0.015616,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1757491200000},"marketStatusCode":5,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":41.04,"postHourTrading":{"tag":"盘后","latestPrice":40.4,"preClose":40.4,"latestTime":"16:10 EDT","volume":34,"amount":1373.36,"timestamp":1757448603723},"volumeRatio":0.276959},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":0.276959,"shares":93167803,"dividePrice":0,"high":40.98,"amplitude":0.015616,"preClose":41.04,"low":40.3391,"week52Low":16.5,"pbRate":"40.26","psRate":"68.65","week52High":48.45,"institutionHeld":0,"latestPrice":40.4,"eps":-0.735552,"divideRate":0,"volume":3944,"delay":0,"ttmEps":-0.735552,"open":40.98,"prevYearClose":17.25,"prevWeekClose":40.4987,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":41.82,"twentyDayClose":40.04,"sixtyDayClose":32.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-09-08","current":-23.478386,"percent":0.980392,"low":-76.454813,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"high":-21.702816,"avg":-42.462654,"sd":14.204425,"marketCap":3817512539.24},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-08","current":-23.478386,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"marketCap":3817512539.24}],"updateTime":1757454103123},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526875562","title":"亞盛醫藥-B：受託人就2022年受限制股份單位計劃購買5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2526875562","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526875562?lang=zh_tw&edition=fundamental","pubTime":"2025-04-09 08:50","pubTimestamp":1744159800,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　亚盛医药-B（06855）发布公告，于2025年4月8日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在行使后满足受限制股份单位。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-09/doc-inesppua6861462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAPG","BK4139","06855","BK1574","BK1161"],"gpt_icon":0},{"id":"2525672890","title":"亞盛醫藥-B(06855)：受託人就2022年受限制股份單位計劃購買5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2525672890","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525672890?lang=zh_tw&edition=fundamental","pubTime":"2025-04-08 21:23","pubTimestamp":1744118596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2025年4月8日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在行使后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1275709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","AAPG","BK1574","06855"],"gpt_icon":0},{"id":"2525750382","title":"亞盛醫藥4月4日成交額為172.07萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525750382","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525750382?lang=zh_tw&edition=fundamental","pubTime":"2025-04-05 09:15","pubTimestamp":1743815712,"startTime":"0","endTime":"0","summary":"美东时间2025年4月4日，亚盛医药成交额为172.07万美元，成交额较昨日增加5.84%，当日成交量为8.14万股。亚盛医药于2025年4月4日跌9.19%，报20.95美元，该股过去5个交易日跌3.23%，年初至今涨21.45%，过去60日涨21.45%。它专注于开发抑制蛋白质间相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理部门包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250405091516a6b0340f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250405091516a6b0340f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2524414932","title":"亞盛醫藥4月3日成交額為162.57萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524414932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524414932?lang=zh_tw&edition=fundamental","pubTime":"2025-04-04 09:15","pubTimestamp":1743729311,"startTime":"0","endTime":"0","summary":"美东时间2025年4月3日，亚盛医药成交额为162.57万美元，成交额较昨日增加38.80%，当日成交量为7.16万股。亚盛医药于2025年4月3日涨0.3%，报23.07美元，该股过去5个交易日涨14.21%，年初至今涨33.74%，过去60日涨33.74%。它专注于开发抑制蛋白质间相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理部门包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250404091515a6af27ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250404091515a6af27ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2524012744","title":"【券商聚焦】浦銀國際予亞盛醫藥(06855)“買入”評級 耐立克獲納醫保 有望在2025年迎來強勁收入增速","url":"https://stock-news.laohu8.com/highlight/detail?id=2524012744","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524012744?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 14:05","pubTimestamp":1743660348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 浦银国际发研报指，亚盛医药 2024年公司实现收入人民币9.81亿元，其中知识产权收入为6.78亿元，耐立克销售收入为2.41亿元，符合市场预期；净亏损为4.06亿元，符合市场预期；研发费用为9.47亿元，销售费用为1.96亿元，同比基本持平。该行表示，耐立克CML-CP全人群适应症已于年初纳入医保，有望在2025年迎来强劲收入增速：中国市场方面，耐立克于2024年在中国实现销售收入2.41亿元。该行预测耐立克今年销售有望翻倍，达到约5亿元销售收入。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1956599","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2524592421","title":"【晨觀方正】亞盛醫藥B公司點評報告新 / 中遠海控2024年報點評 20250403","url":"https://stock-news.laohu8.com/highlight/detail?id=2524592421","media":"方正证券研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524592421?lang=zh_tw&edition=fundamental","pubTime":"2025-04-03 08:31","pubTimestamp":1743640261,"startTime":"0","endTime":"0","summary":"“晨观方正”将为大家带来：行业时事亚盛医药B公司点评报告中远海控2024年报点评行业时事医药 | 周超泽亚盛医药B公司点评报告事件：亚盛医药2024年实现收入人民币9.81亿元，同比增长342%；净亏损4.06亿元，同比收窄56.2%；研发开支9.47亿元，同比增长34%；货币资金12.6亿元。2024年，耐立克实现销售收入达人民币2.41亿元，同比增长52%。截至2024年底，现金储备12.61亿元，同比增长15.3%，为持续研发提供保障。AACR 2025年会公司预计公布5项研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403083532a6adcb38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250403083532a6adcb38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0270","BK0196","BK0012","BK0028","BK0013","BK0010","601919","01919","150131","AAPG","BK0006"],"gpt_icon":0},{"id":"2524490060","title":"亞盛醫藥上漲2.1%，報23.524美元/股，總市值20.48億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524490060","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524490060?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 23:03","pubTimestamp":1743606221,"startTime":"0","endTime":"0","summary":"4月2日，亚盛医药盘中上涨2.1%，截至23:03，报23.524美元/股，成交27.8万美元，总市值20.48亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/02230349261364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2524849391","title":"亞盛醫藥：全球化戰略加速，雙引擎驅動商業化高速發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2524849391","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524849391?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 20:41","pubTimestamp":1743597661,"startTime":"0","endTime":"0","summary":"“面对生物医药产业的挑战，我相信今年将是一个新的起点和转折点。我也坚信，健康始终是一个朝阳行业，尤其是在中国经过三四十年的改革开放后，我们已经建立了坚实的经济基础，拥有优质的人才和巨大的市场需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504023363794130.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504023363794130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2524177630","title":"亞盛醫藥4月1日成交額為160.94萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524177630","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524177630?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 09:15","pubTimestamp":1743556512,"startTime":"0","endTime":"0","summary":"美东时间2025年4月1日，亚盛医药成交额为160.94万美元，成交额较昨日增加257.97%，当日成交量为7.03万股。亚盛医药于2025年4月1日涨4.97%，报23.04美元，该股过去5个交易日涨24.81%，年初至今涨33.57%，过去60日涨33.57%。它专注于开发抑制蛋白质间相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理部门包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402091525a6ac8bf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402091525a6ac8bf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2524148761","title":"亞盛醫藥上漲4.53%，報22.945美元/股，總市值19.98億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2524148761","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524148761?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 22:35","pubTimestamp":1743518134,"startTime":"0","endTime":"0","summary":"4月1日，亚盛医药盘中上涨4.53%，截至22:35，报22.945美元/股，成交21.62万美元，总市值19.98亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/01223549226330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"1197795490","title":"異動解讀 | 亞盛醫藥盤中大漲5.56%，創新藥佈局和業績增長獲市場認可","url":"https://stock-news.laohu8.com/highlight/detail?id=1197795490","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197795490?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 21:46","pubTimestamp":1743515194,"startTime":"0","endTime":"0","summary":"4月1日盘中，亚盛医药股价大涨5.56%，引发市场关注。分析人士认为，这一涨幅可能与公司近期公布的强劲财务业绩以及创新药物研发进展密切相关。根据亚盛医药最新发布的财报，公司2024年收入达到9.8亿元，同比增长342%。在当前生物医药行业整体面临挑战的背景下，亚盛医药的业绩表现尤为亮眼，显示出公司的经营实力和市场竞争力。随着公司管线产品的不断推进和商业化能力的提升，亚盛医药有望在全球创新药企中占据更重要的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"1133352780","title":"異動解讀 | 亞盛醫藥盤中大漲5.56%，業績超預期及產品管線進展引關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1133352780","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133352780?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 21:46","pubTimestamp":1743515191,"startTime":"0","endTime":"0","summary":"4月1日盘中，亚盛医药股价大涨5.56%，引发市场广泛关注。这一强劲涨势背后，是公司近期发布的亮眼财报以及产品管线的重大进展。根据亚盛医药最新发布的财报显示，公司2024年度收入达到9.8亿元，同比大幅增长342%。除了财务表现外，亚盛医药在产品管线方面也取得了重大突破。市场普遍认为，随着这些产品的陆续获批和商业化，亚盛医药有望持续保持高速增长态势。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 亚盛医药盘中大涨5.56%，业绩超预期及产品管线进展引关注","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2524158601","title":"亞盛醫藥全速前進背後","url":"https://stock-news.laohu8.com/highlight/detail?id=2524158601","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524158601?lang=zh_tw&edition=fundamental","pubTime":"2025-04-01 14:04","pubTimestamp":1743487477,"startTime":"0","endTime":"0","summary":"亚盛医药迎来了其史上收入最高的年份。财务数字体现了亚盛医药的经营成果质量。然而，财务数字并未完全展现亚盛医药的全部成就。看得出来，亚盛医药在加速前进。对此，资本市场给予了极大的认可，财报发布后，亚盛医药美股ADR连续两天大涨，累计涨幅接近20%；港股同样表现强劲。虽然亚盛医药尚未到达终点，但其持续加速的过程，已经给产业带来了诸多启示。而亚盛医药，是自始至终坚持下来的选手。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/254345","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2523926714","title":"亞盛醫藥-B(06855)：受託人就2022年受限制股份單位計劃購買5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2523926714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523926714?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 23:06","pubTimestamp":1743433566,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2025年3月31日，受托人就2022年受限制股份单位计划目的于场内购买合共50000股现有股份以在行使后满足受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1272129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4139","06855","AAPG","BK1161"],"gpt_icon":0},{"id":"2523960605","title":"年入9.81億元，同比高增342%，亞盛醫藥的“雪球越滾越大”","url":"https://stock-news.laohu8.com/highlight/detail?id=2523960605","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523960605?lang=zh_tw&edition=fundamental","pubTime":"2025-03-31 15:35","pubTimestamp":1743406500,"startTime":"0","endTime":"0","summary":"亚盛医药在2024年实现营收9.81亿元，同比增长342%，净亏损收窄至4.05亿元。其核心产品耐立克®（奥雷巴替尼）销售收入达2.41亿元，同比增长52%。该药物作为中国首个获批治疗T315I突变慢性髓细胞白血病的BCR-ABL1 TKI，已在734家医院和DTP药房落地。亚盛医药通过国际临床试验推进、创纪录BD达成及美股上市等举措，正逐步迈向全球肿瘤创新领域的领导者地位。公司董事长杨大俊博士表示，技术创新是驱动变革的关键。耐立克®的多项临床数据也在美国血液学会年会上展示，进一步证明了其市场潜力和竞争优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025033115461794c71345&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025033115461794c71345&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","AAPG","06855","BK1574"],"gpt_icon":0},{"id":"1176748047","title":"異動解讀 | 亞盛醫藥財報亮眼，盤中大漲6.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176748047","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176748047?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 21:34","pubTimestamp":1743168870,"startTime":"0","endTime":"0","summary":"周五盘中，亚盛医药股价大涨6.44%，引发市场广泛关注。这一显著涨幅主要源于公司日前发布的2024年度财报中披露的亮眼业绩。根据亚盛医药公布的2024年全年业绩报告，公司实现营收9.81亿元人民币，同比大幅增长342%。除了财务表现优异外，亚盛医药在产品开发和商业化方面也取得了显著进展。此外，亚盛医药今年1月成功登陆美国纳斯达克市场，成为2025年美股生物医药第一股，进一步彰显了其全球化战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"1190695404","title":"異動解讀 | 亞盛醫藥盤中大漲6.44%，年度營收暴增342%引發投資者熱情","url":"https://stock-news.laohu8.com/highlight/detail?id=1190695404","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190695404?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 21:34","pubTimestamp":1743168870,"startTime":"0","endTime":"0","summary":"亚盛医药今日盘中大涨6.44%，引发市场广泛关注。这一显著涨幅主要源于公司近期发布的2024年全年业绩报告，以及其核心产品的强劲表现。根据亚盛医药公布的2024年财报，公司实现营业收入9.81亿元人民币，同比大幅增长342%。除了财务业绩外，亚盛医药在产品开发和商业化方面也取得了重要进展。这些进展不仅巩固了亚盛医药在国内市场的地位，也为其国际化战略奠定了基础，进一步提升了投资者对公司未来发展前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 亚盛医药盘中大涨6.44%，年度营收暴增342%引发投资者热情","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2522093572","title":"拳頭產品國內銷售大增52%，亞盛醫藥去年虧損收窄，欲挑戰艾伯維血液腫瘤明星藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2522093572","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522093572?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 21:10","pubTimestamp":1743167405,"startTime":"0","endTime":"0","summary":"营收的大幅增长主要得益于武田制药的知识产权收入及药品销售增加。目前，耐立克所有获批适应症均已纳入国家医保药品目录。此外，武田制药还决定认购亚盛医药新发行的7500万美元股份，成为公司第二大股东。报告期内，亚盛医药已经收到来自武田制药的1.75亿美元付款。受益于此，截至报告期末，亚盛医药的现金及银行结余同比增长15.3%，达12.61亿元。目前，亚盛医药正在开展十项注册临床研究，其中两项获美国食品药品监督管理局许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032821104094c441b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032821104094c441b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","AAPG","BK1161"],"gpt_icon":0},{"id":"2522564678","title":"亞盛醫藥-B績後漲超8% 公司全年收入同比增長342%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522564678","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522564678?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 10:29","pubTimestamp":1743128940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　亚盛医药-B（06855）绩后再涨9%，截至发稿，股价上涨8.24%，现报43.35港元，成交额2.15亿港元。\n　　亚盛医药公布2024年全年业绩。报告期内，亚盛医药核心产品耐立克展现增长强劲态势，实现销售收入2.41亿元人民币，同比增长52%。亚盛医药2024全年实现收入9.81亿元人民币，较去年同比增长342%，增长主要来源于产品销售收入和对外合作授权收入等。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-28/doc-inerenpv1412789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06855","BK1574","BK4139","AAPG","BK1161"],"gpt_icon":0},{"id":"2522610265","title":"港股異動 | 亞盛醫藥-B(06855)績後再漲9% 耐立克銷售額顯著增長 公司全年收入增超3.4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2522610265","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522610265?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 10:20","pubTimestamp":1743128442,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B绩后再涨9%，截至发稿，涨8.74%，报43.55港元，成交额2.02亿港元。消息面上，亚盛医药公布2024年全年业绩。报告期内，亚盛医药核心产品耐立克展现增长强劲态势，实现销售收入2.41亿元人民币，同比增长52%。值得注意的是，报告期内，亚盛医药与武田就耐立克达成独家选择权协议，创下截至目前国内小分子肿瘤药领域的最大的对外权益许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1269746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","AAPG","BK1574","06855"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":172,"code":"91000000","status":"200"}]}}